JP2007529220A - 栄養補助食品及び消化器系関連障害の治療方法 - Google Patents
栄養補助食品及び消化器系関連障害の治療方法 Download PDFInfo
- Publication number
- JP2007529220A JP2007529220A JP2007503889A JP2007503889A JP2007529220A JP 2007529220 A JP2007529220 A JP 2007529220A JP 2007503889 A JP2007503889 A JP 2007503889A JP 2007503889 A JP2007503889 A JP 2007503889A JP 2007529220 A JP2007529220 A JP 2007529220A
- Authority
- JP
- Japan
- Prior art keywords
- dietary supplement
- supplement
- dietary
- oil
- polar lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 245
- 230000001079 digestive effect Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 28
- 150000002632 lipids Chemical class 0.000 claims abstract description 91
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 55
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 55
- 239000000835 fiber Substances 0.000 claims abstract description 50
- 210000002249 digestive system Anatomy 0.000 claims abstract description 43
- 208000035475 disorder Diseases 0.000 claims abstract description 43
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 230000009286 beneficial effect Effects 0.000 claims abstract description 22
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 239000013589 supplement Substances 0.000 claims description 64
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 50
- 239000003921 oil Substances 0.000 claims description 49
- 235000019198 oils Nutrition 0.000 claims description 49
- 244000075850 Avena orientalis Species 0.000 claims description 46
- 235000007319 Avena orientalis Nutrition 0.000 claims description 46
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 45
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000004473 Threonine Substances 0.000 claims description 32
- 229960002898 threonine Drugs 0.000 claims description 32
- 229940024606 amino acid Drugs 0.000 claims description 30
- 230000002496 gastric effect Effects 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 239000004615 ingredient Substances 0.000 claims description 25
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims description 24
- 229930182816 L-glutamine Natural products 0.000 claims description 21
- 244000052616 bacterial pathogen Species 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 16
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 235000005911 diet Nutrition 0.000 claims description 14
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 13
- 201000010927 Mucositis Diseases 0.000 claims description 13
- 208000025865 Ulcer Diseases 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 13
- 210000000987 immune system Anatomy 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 231100000678 Mycotoxin Toxicity 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- 239000002636 mycotoxin Substances 0.000 claims description 12
- 206010006895 Cachexia Diseases 0.000 claims description 11
- 230000037213 diet Effects 0.000 claims description 11
- 231100000397 ulcer Toxicity 0.000 claims description 11
- 208000011231 Crohn disease Diseases 0.000 claims description 10
- 206010013554 Diverticulum Diseases 0.000 claims description 10
- 235000019486 Sunflower oil Nutrition 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000002600 sunflower oil Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 208000003265 stomatitis Diseases 0.000 claims description 8
- 208000007784 diverticulitis Diseases 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 235000005687 corn oil Nutrition 0.000 claims description 4
- 239000002285 corn oil Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 235000015816 nutrient absorption Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 230000000378 dietary effect Effects 0.000 claims description 3
- 239000000446 fuel Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 235000011649 selenium Nutrition 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 229910052720 vanadium Inorganic materials 0.000 claims description 3
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000011785 micronutrient Substances 0.000 claims description 2
- 235000013369 micronutrients Nutrition 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 230000008821 health effect Effects 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 235000021055 solid food Nutrition 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 description 26
- 229940079593 drug Drugs 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 24
- 208000018522 Gastrointestinal disease Diseases 0.000 description 19
- 230000000968 intestinal effect Effects 0.000 description 17
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 230000009102 absorption Effects 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 11
- 210000003097 mucus Anatomy 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 235000013312 flour Nutrition 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 201000010538 Lactose Intolerance Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 229960004963 mesalazine Drugs 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229940038580 oat bran Drugs 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- 240000000491 Corchorus aestuans Species 0.000 description 3
- 235000011777 Corchorus aestuans Nutrition 0.000 description 3
- 235000010862 Corchorus capsularis Nutrition 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010059881 Lactase Proteins 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 208000035474 group of disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 230000003843 mucus production Effects 0.000 description 3
- 210000003007 myelin sheath Anatomy 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 235000021231 nutrient uptake Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 235000021400 peanut butter Nutrition 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 235000021310 complex sugar Nutrition 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229940063148 rowasa Drugs 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- -1 B12 Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000001104 Digestive System Abnormalities Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006047 digesta Substances 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000012493 hydrazine sulfate Substances 0.000 description 1
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 238000009925 jellying Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940072223 pentasa Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000012423 response to bacterium Effects 0.000 description 1
- 230000024622 response to vitamin Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940106721 tagamet Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940108322 zantac Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
Abstract
【選択図】図1
Description
上で議論した背景技術の不利益及び制約は、本発明によって解消される。本発明では、多くの消化管疾患及び同様に多くの消化管関連障害を治療及び/又は予防するための新規な栄養補助食品が提供される。本発明によって教示される方法に従って、ヒト又は他の動物に対するこの栄養補助食品によって、多くの消化管疾患及び多くの消化管関連の障害が、そのようなヒト及び他の動物に対して効果的に治療及び/又は予防される。当業者に対して迅速に明らかになるように、本発明の栄養補助食品は、それ自体で作用する各成分がヒト又は他の動物に提供される場合にもたらされるであろう結果よりも、実質的でより有効な相乗効果をもたらす成分の組み合わせによって、その成分の合計よりも一層有効である。
血流に水溶性及び脂溶性栄養分(及び薬物)の吸収を強化するであろう、また、酸化防止剤を提供する、乳化剤として機能するために極性脂質を提供することによって;
免疫系への強力な刺激を提供することによって、血流でLDLコレステロールの画分を減少させ、血糖を安定させることによって;及び、
特にストレスにさらされた消化器系に有益である方法で消化管粘膜の健全性を増大することによって、
成分間の相互作用により強化されるように機能する。好ましい実施形態において、さらなる成分は、病原性バクテリアに結合し及び消失させ、マイコトキシンを吸着又は吸収するために、本発明の栄養補助食品に含まれ、成長で調整経路をコントロールして、病気に対する免疫を提供する代謝機能をサポートする。
本発明の栄養補助食品のこの適用は、当初、単胃で、散発的に食べること又は高いストレスを含む状況下で腸の潰瘍になりやすい、ヒトのような、ウマ科の動物の患者での研究に基づいた。栄養補助食品は、可溶性β−グルカン繊維を含み、それは食物繊維を加え、消化プロセスを遅らせ、胃で胃液を緩衝し、可溶性β−グルカン繊維は、強力な免疫系刺激物である。また、腸の表面を覆い、腸の内側を覆っている腸細胞の不浸透性を向上させる極性脂質を含む。グルタミン及びトレオニンは、粘液の生成において重要であることを知られており、それは腸を全体にわたって酸、ペプチド及び病原体からのさらなる保護を提供する。
本発明の栄養補助食品のこの適用は、大腸炎の人々がこの痛みを伴う胃症候群の衰弱する状況を克服するのを助けることができる。可溶性β−グルカン繊維は、栄養分の吸収を和らげ、敏感な消化器系に対するショックを低減することを助ける。さらに、可溶性β−グルカン繊維は、消化物に食物繊維を加えることを助け、下痢及び便秘を低減させる。極性脂質の製剤への追加は、消化管の内側をおおうことを助け、この病気に関係する酸及び病原体が浸潤しないようにする。
本発明の栄養補助食品のこの適用は、過敏性大腸症候群の人々がこの痛みを伴う衰弱する状況を克服するのを助けることができる。可溶性β−グルカン繊維は、栄養分の吸収を和らげ、敏感な消化器系に対するショックを低減することを助ける。さらに、可溶性β−グルカン繊維は、消化物に食物繊維を加えることを助け、下痢及び便秘を低減させる。極性脂質の製剤への追加は、消化管の内側をおおうことを助け、この病気に関係する酸及び病原体が浸潤しないようにする。
憩室炎は、小腸ポケット又は憩室において食物小片が閉じ込められることに起因する。本発明の栄養補助食品のこの適用は、腸の流れが、食事における可溶性β−グルカン繊維の存在によって改善されることが観察されたことに基づく。可溶性β−グルカン繊維は、通過時間が遅れるのを助け、体がよりよく食品を消化することを助ける。可溶性β−グルカン繊維はゲルを形成し、食物小片を引き離すことを助け、小片を残さない可能性を高める食物塊をつくる。さらに、製剤は、消化器系をおおうことを助ける極性脂質を含み、その不浸透性を向上させて、それをより滑りやすくする。これは、小片がひっかかって、憩室に集まらないようにすることを助ける。
本発明の栄養補助食品は、クローン病の人々を助けることができ、それは腸の上皮バリアの漏れやすさに起因する。本発明の栄養補助食品のこの適用は、極性脂質が消化管を覆い、腸の上皮の健全性を増大することを助けるという観察に基づく。製剤のグルタミン及びトレオニンは、粘液産生に寄与し、ストレスにさらされた腸細胞の健康を増進する。グルタミンが腸の組織の漏れやすさを低減することも知られており、未治療である場合、それはグラム陰性バクテリアによって感染を招くかもしれない。また、本発明の栄養補助食品は、免疫系を刺激する可溶性β−グルカン繊維を含み、さらに細胞腸壁を破壊する病原体に対して防護することを助ける。
本発明の栄養補助食品のこの適用は、放射線又は化学療法によって誘導される口内炎及び粘膜炎を低減させるか、除くことができる。この適用は、製剤は、人々が、吐き気、出血、膨満、痛み及び一般的に多くのガン療法を伴う下痢を克服することを助けることができるという証拠に基づく。これらの治療は、有糸分裂(細胞分裂)のプロセスにおいて細胞を殺すことによって、迅速に発達するガンを停止することを意図する。副作用として、迅速に分割する上皮細胞も殺され、口内炎をもたらし、粘膜炎と呼ばれているよりひどい症候群へ進行する。
本発明の栄養補助食品のこの適用は、消耗性疾患又は悪液質の人を助けることができ、体重を増やし、よって彼らの回復を速くする。グルタミンは、悪液質であるHIV患者のために役に立つと確認された。グルタミンは、豊富なアミノ酸であるが、ストレスにさらされた場合、消化器系は、その高い成長率を維持させるのに十分に摂取できないかもしれない。本発明の栄養補助食品は、このアミノ酸の生物学的利用能を改善するために、極性脂質に加えてグルタミンを含む。また、トレオニンも含み、それは粘液を発生経路の肝要な一部である。粘液は、次に、体と消化物との間の障壁を維持するのを助ける。このバリアを強化することは、浪費をもたらし得る血又は血清の損失を防止することを助けるかもしれない。
本発明の栄養補助食品のこの適用は、ラクトース不耐性の不快な副作用を低減又は排除することができる。この適用は、製剤が、一般的に彼らに吐き気をもようさせる乳製品に耐性を与えることについて人々を助けることができるという証拠に基づく。製剤中の物質は、消化物の輸送を遅らせることを助けると思われており、ラクターゼを低レベルで有する人々が、ラクトースを含む食品の消化のため、より多くの時間を確保するのを助ける。
本発明の栄養補助食品のこの適用は、年配者がより効果的に損なわれた消化器系に対処することを助けることができる。この適用は、グルタミン及び可溶性β−グルカン繊維が腸の筋緊張を増加し、免疫系を刺激することを助けることができるという証拠に基づく。可溶性β−グルカン繊維で消化物の輸送が遅れることは知られており、それは食物塊を和らげ、同時に、便秘を最小限にする膨張性薬剤を提供する間、水を再吸収させて、下痢を阻止する。結果は、より良好な経口、より良好な予想通りの消失及びより胃のストレス解消をもたらす。
本発明の栄養補助食品のこの用途は、糖尿病患者が、彼らのインシュリンを減量するか、除去するのさえ助けることができる。この用途は、可溶性β−グルカン繊維で消化物の輸送を遅らせることができるという証拠に基づき、それは食事の血糖インデックスを低減させる。可溶性β−グルカン繊維は、澱粉及び糖を吸収し、取り除くことができる食物繊維であり、より長い時間にわたってそれらを放出する。低い血糖インデックスを導き、血液に遅く糖を放出する。これはインシュリンが血糖値の大きな変動に反応する必要を低減させ、すい臓に障害のある人々が、より良好に彼らの栄養に対処することができる。彼らが本発明の栄養補助食品を使い続ける限り、わずかに糖尿病の傾向だけをもつ人々は、インシュリンの毎日の投与を控えることができるかもしれない。
本発明の栄養補助食品のこの適用は、多発性硬化症又は他のミエリンが不足している病気(筋萎縮性側索硬化症(ALS)又は潜在的アルツハイマー病等)に対して人々を助けることができる。この適用は、ガラクトリピドが、神経細胞を絶縁するミエリン鞘の重要な構成要素であるという観察に基づき、細胞に細胞からの低騒音伝達を可能にする。ミエリン鞘は、乏枝神経膠細胞と呼ばれている細胞によって産生され、それは平らで、ニューロン軸索のまわりに巻きつくプロセスを送り出す。また、本発明の栄養補助食品は、ビタミンE(トコフェロール)を取り入れ、それは乏枝神経膠細胞の健康の潜在的一因として示される。
Claims (62)
- 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品であって、
極性脂質及び酸化防止剤の相当量を含む極性脂質補助食品、
少なくとも1つの健康に有益な作用を与える可溶性β−グルカン繊維、
消化器系に少なくとも1つの有益な作用を与える少なくとも1つのアミノ酸を含む栄養補助食品。 - 極性脂質補助食品はオート麦の脂質を含む請求項1の栄養補助食品。
- 極性脂質補助食品は、オート麦油、ヒマワリ油、大豆油、オリーブ油、パーム油、トウモロコシ油、菜種油、亜麻仁油からなる群から選択される少なくとも1種からなる請求項1の栄養補助食品。
- 極性脂質補助食品はオート麦油を含む請求項1の栄養補助食品。
- オート麦油は、抽出プロセスの全ての相の混合物を含む請求項4の栄養補助食品。
- 極性脂質補助食品は、さらに抽出プロセスの最終相からのオート麦油を含み、該抽出プロセスの最終相からのオート麦油は粘稠で比較的高い粘度を有する請求項4の栄養補助食品。
- 極性脂質補助食品が、さらにヒマワリ油、大豆油、オリーブ油、パーム油、トウモロコシ油、菜種油及び亜麻仁油からなる群から選択される少なくとも1つの添加油を含む請求項4の栄養補助食品。
- オート麦油は、約25パーセントの極性脂質からなる請求項4の栄養補助食品。
- 極性脂質補助食品は、栄養補助食品の約10から60重量パーセント含む請求項1の栄養補助食品。
- 極性脂質補助食品は、栄養補助食品の約40から55重量パーセント含む請求項9の栄養補助食品。
- 極性脂質補助食品は、栄養補助食品の約48重量パーセント含む請求項10の栄養補助食品。
- 可溶性β−グルカン繊維はオート麦由来である請求項1の栄養補助食品。
- 可溶性β−グルカン繊維は、栄養補助食品の約1から50重量パーセント含む請求項1の栄養補助食品。
- 可溶性β−グルカン繊維は、栄養補助食品の約15から30重量パーセント含む請求項1の栄養補助食品。
極性脂質補助食品はオート麦油を含む請求項1の栄養補助食品。 - 可溶性β−グルカン繊維は、栄養補助食品の約23重量パーセント含む請求項1の栄養補助食品。
- 少なくとも1つのアミノ酸はL−トレオニンを含む請求項1の栄養補助食品。
- L−トレオニンは、栄養補助食品の約1から20重量パーセント含む請求項16の栄養補助食品。
- L−トレオニンは、栄養補助食品の約5から15重量パーセント含む請求項17の栄養補助食品。
- L−トレオニンは、栄養補助食品の約11重量パーセント含む請求項1の栄養補助食品。
- 少なくとも1つのアミノ酸はL−グルタミンを含む請求項1の栄養補助食品。
- L−グルタミンは、栄養補助食品の約2から20重量パーセント含む請求項1の栄養補助食品。
- L−グルタミンは、栄養補助食品の約5から15重量パーセント含む請求項1の栄養補助食品。
- L−グルタミンは、栄養補助食品の約9重量パーセント含む請求項1の栄養補助食品。
- さらに、消化管において病原バクテリアを吸収及び消失させるニュートリシンを含む請求項1の栄養補助食品。
- 消化管において病原バクテリアを吸収及び消失させるニュートリシンは、マンナンオリゴサッカライド(MOS)を含む請求項24の栄養補助食品。
- 消化管において病原バクテリアを吸収及び消失させるニュートリシンは、S.I. Lesaffreによる商標SAFMANNANとして市販された材料を含む請求項26の栄養補助食品。
- 消化管において病原バクテリアを吸収及び消失させるニュートリシンは、栄養補助食品の約1.5から10重量パーセント含む請求項24の栄養補助食品。
- 消化管において病原バクテリアを吸収及び消失させるニュートリシンは、栄養補助食品の約3から7重量パーセント含む請求項27の栄養補助食品。
- 消化管において病原バクテリアを吸収及び消失させるニュートリシンは、栄養補助食品の約5重量パーセント含む請求項28の栄養補助食品。
- 消化管においてマイコトキシンを吸収及び消失させるニュートリシンを含む請求項1の栄養補助食品。
- 消化管においてマイコトキシンを吸収及び消失させるニュートリシンはサッカロマイセス・セレヴィシエに基づく請求項30の栄養補助食品。
- 消化管においてマイコトキシンを吸収及び消失させるニュートリシンはAlltech, Incによる商標MYCOSORBで市販された材料を含む請求項30の栄養補助食品。
- 消化管においてマイコトキシンを吸収及び消失させるニュートリシンは、栄養補助食品の約1から5重量パーセント含む請求項30の栄養補助食品。
- さらに、成長を増進させ及び/又は免疫系を強化するニュートリシンを含む請求項1の栄養補助食品。
- 成長を増進させ及び/又は免疫系を強化するニュートリシンは、食物ヌクレオチド含有補助食品を含む請求項34の栄養補助食品。
- ヌクレオチド含有補助食品は、栄養補助食品の約1重量パーセント含み、栄養補助食品中のヌクレオチド濃度が栄養補助食品の約0.01から1.5重量パーセントである請求項35の栄養補助食品。
- 成長を増進させ及び/又は免疫系を強化するニュートリシンが、ビール酵母又はパン酵母由来である請求項34の栄養補助食品。
- 成長を増進させ及び/又は免疫系を強化するニュートリシンが、S.I. Lesaffreによる商標YEAST CELL EXTRACT(2006)で市販された材料を含む請求項34の栄養補助食品。
- さらに、栄養補助食品の構成成分の分離を防止する乳化剤を含む請求項1の栄養補助食品。
- 乳化剤が、グアーガムを含む請求項39の栄養補助食品。
- 栄養補助食品の構成成分の分離を防止する乳化剤が、栄養補助食品の約1重量パーセント含まれる請求項39の栄養補助食品。
- 栄養補助食品の他の成分とともに収容される医薬品を含み、該医薬品の少なくとも1つの吸収又は治療値を前記栄養補助食品との組み合わせによって最大化する請求項1の栄養補助食品。
- 栄養補助食品が固体食品バーとして形成される請求項1の栄養補助食品。
- 栄養補助食品がペーストとして形成される請求項1の栄養補助食品。
- 栄養補助食品が顆粒固体として形成される請求項1の栄養補助食品。
- 栄養補助食品が粉末として形成される請求項1の栄養補助食品。
- 栄養補助食品が液体として形成される請求項1の栄養補助食品。
- 栄養補助食品が液体充填ソフトゲルカプセルとして形成される請求項1の栄養補助食品。
- 消化器系疾患は、潰瘍、大腸炎、過敏性大腸症候群、憩室症、憩室炎、クローン病、粘膜炎及び口内炎からなる群から選択される請求項1の栄養補助食品。
- 消化器系関連した障害は、悪液質、ラクトース狭量、年輩者の食事の不足、糖尿病、多発性硬化症及び他の神経変性病気からなる群から選択される請求項1の栄養補助食品。
- さらに、ビタミンB6、ビタミンB12、ビオチン、ビタミンC、ビタミンE及びナイアシンからなる群から選択される少なくとも1つのビタミンを含む請求項1の栄養補助食品。
- さらに、クロミウム、銅、マンガン、マグネシウム、マンガン、カリウム、セレン、バナジウム及び亜鉛からなる群から選択される少なくとも1つのミネラルのマイクロ栄養添加物を含む請求項1の栄養補助食品。
- 毎日約1グラムから約30グラムの前記栄養補助食品の1日用量をとることによって、極性脂質補助食品、可溶性β−グルカン繊維、少なくとも1つのアミノ酸の有効両量を与える請求項1の栄養補助食品。
- さらに、栄養補助食品の他の成分とともに収容される医薬品を含み、該医薬品の少なくとも1つの吸収又は治療値を前記栄養補助食品と組み合わせて摂取することによって最大化する請求項1の栄養補助食品。
- 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品であって、
極性脂質及び酸化防止剤の相当量を含む極性脂質補助食品、
少なくとも1つの健康に有益な作用を与える可溶性β−グルカン繊維、
代謝及び栄養吸収を助ける第1界面活性アミノ酸ベースニュートリシン、
筋肉の燃料であり、消化器系の免疫機能をサポートする第2界面活性アミノ酸ベースニュートリシンを含む栄養補助食品。 - 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品であって、
極性脂質及び酸化防止剤の相当量を含む極性脂質補助食品、
可溶性β−グルカン繊維、
L−トレオニン、
L−グルタミン及び
消化管で病原性バクテリアを吸収及び消失させるニュートリシンを含む栄養補助食品。 - 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品であって、
有効量の極性脂質補助食品、
有効量のβ−グルカン、
有効量のL−トレオニン及び
有効量のL−グルタミンを含む栄養補助食品。 - 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品であって、
一日用量約25mgから約4500mgの極性脂質を含む極性脂質補助食品、
少なくとも1つの健康に有益な作用を与える可溶性β−グルカン繊維、及び
ストレスにさらされた消化器系に少なくとも1つの有益な作用を長期にわたって働かせることができる少なくとも1つのアミノ酸を含む栄養補助食品。 - 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品であって、
極性脂質補助食品、
可溶性β−グルカン繊維、及び
アミノ酸を含む栄養補助食品。 - 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品の製造方法であって、
極性脂質及び酸化防止剤の相当量を含む極性脂質補助食品を準備し、
少なくとも1つの健康に有益な作用を与える可溶性β−グルカン繊維を準備し、
ストレスにさらされた消化器系に少なくとも1つの有益な作用を長期にわたって働かせることができる少なくとも1つのアミノ酸を準備し、
前記極性脂質補助食品、可溶性β−グルカン繊維及び、ストレスにさらされた消化器系に少なくとも1つの有益な作用を長期にわたって働かせることができる1つのアミノ酸を一緒に混合することを含む方法。 - 消化障害並びに消化器系に関連する疾患の治療及び予防用栄養補助食品の製造方法であって、
極性脂質補助食品を準備し、
可溶性β−グルカン繊維を準備し、
ストレスにさらされた消化器系に少なくとも1つの有益な作用を長期にわたって働かせることができる少なくとも1つのアミノ酸を準備し、
L−トレオニンを準備し、
L−グルタミンを準備し、
消化管で病原性バクテリアを吸収及び消失させるニュートリシン、
前記極性脂質補助食品、可溶性β−グルカン繊維、L−トレオニン、L−グルタミン及び、消化管で病原性バクテリアを吸収及び消失させるニュートリシンを一緒に混合することを含む方法。 - 消化障害並びに消化器系に関連する疾患の治療において使用される予防用栄養補助食品の投与方法であって、
極性脂質及び酸化防止剤の相当量を含む極性脂質補助食品、
少なくとも1つの健康に有益な作用を与える可溶性β−グルカン繊維、
ストレスにさらされた消化器系に少なくとも1つの有益な作用を長期にわたって働かせることができる少なくとも1つのアミノ酸を含む栄養補助食品の適当用量を調製し、
定期的に前記栄養補助食品を投与し、
前記調製及び投与工程を少なくとも1日1回繰り返すことを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/802,342 US7988989B2 (en) | 2003-05-09 | 2004-03-17 | Nutritional product for enhancing growth and/or strengthening the immune system of equine foals |
US10/947,598 US20050058671A1 (en) | 2003-05-09 | 2004-09-22 | Dietary supplement and method for treating digestive system-related disorders |
PCT/US2004/036720 WO2005094234A2 (en) | 2004-03-17 | 2004-11-03 | Dietary supplement for treating digestive system disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010060286A Division JP2010162040A (ja) | 2004-03-17 | 2010-03-17 | 栄養補助食品及び消化器系関連障害の治療方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007529220A true JP2007529220A (ja) | 2007-10-25 |
Family
ID=35064222
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503889A Pending JP2007529220A (ja) | 2004-03-17 | 2004-11-03 | 栄養補助食品及び消化器系関連障害の治療方法 |
JP2013098495A Pending JP2013146281A (ja) | 2004-03-17 | 2013-05-08 | 栄養補助食品 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013098495A Pending JP2013146281A (ja) | 2004-03-17 | 2013-05-08 | 栄養補助食品 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050058671A1 (ja) |
EP (1) | EP1729809A4 (ja) |
JP (2) | JP2007529220A (ja) |
KR (1) | KR20070006843A (ja) |
AR (1) | AR047308A1 (ja) |
AU (1) | AU2004317895B2 (ja) |
BR (1) | BRPI0418681A (ja) |
CA (1) | CA2559755C (ja) |
JO (1) | JO2792B1 (ja) |
MX (1) | MXPA06010503A (ja) |
TW (1) | TWI367728B (ja) |
WO (1) | WO2005094234A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012503615A (ja) * | 2008-09-26 | 2012-02-09 | バイオイベリカ ソシエダッド アノニマ | ヌクレオ塩基(nucleobase)と、真菌類、酵母、または細菌から得られる多糖と、を含む免疫刺激剤組成物 |
JP2013095702A (ja) * | 2011-11-01 | 2013-05-20 | Daiso Co Ltd | β−1,3−グルカンを含む過敏性腸症候群の下痢抑制剤、腹痛改善剤、及び大腸における痛覚過敏改善剤 |
JP2017522308A (ja) * | 2014-07-21 | 2017-08-10 | ネステク ソシエテ アノニム | 安全な嚥下を促進する嚥下障害者用栄養製品 |
JP7431842B2 (ja) | 2018-10-15 | 2024-02-15 | フリーダム ヘルス,エルエルシー | 消化器系及び免疫系の障害を治療する為のヒト用栄養補助食品 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8992999B2 (en) * | 2004-06-25 | 2015-03-31 | Alltech, Inc. | Methods and compositions for controlling parasitic infections of animals |
MX2007013725A (es) | 2005-05-05 | 2008-04-09 | Sensient Flavors Inc | Produccion de beta-glucanos y mananos. |
US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8202546B2 (en) * | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
EP1965809B9 (en) | 2005-11-21 | 2010-07-21 | Bioatlantis Limited | Compositions to improve gut health and animal performance comprising beta-glucans and alfa-fucans |
WO2007149437A1 (en) * | 2006-06-16 | 2007-12-27 | Alltech, Inc. | Reduction of antibiotic resistance in bacteria |
DE102006046960A1 (de) * | 2006-10-04 | 2008-04-10 | Euro Allianz Pharma Gmbh | Gesundheitsfördernde Nahrungsmittelzusammensetzung |
CA2705642A1 (en) * | 2007-11-13 | 2009-05-22 | Biotec Pharmacon Asa | Methods of treating or preventing inflammatory diseases of the intestinal tract |
CN101570769B (zh) * | 2008-04-29 | 2013-06-19 | 安琪酵母股份有限公司 | 一种酵母葡聚糖、甘露聚糖及其生产方法 |
EP2241198A1 (en) * | 2009-04-07 | 2010-10-20 | Fresenius Kabi Deutschland GmbH | Mucositis prevention supplement and treatment |
US20110123677A1 (en) * | 2009-11-25 | 2011-05-26 | Pepsico, Inc. | High acid beverage products and methods to extend probiotic stability |
US20120269929A1 (en) * | 2011-04-22 | 2012-10-25 | Hugh Lippman | Fortified Milk-Based Nutritional Compositions |
US9616041B2 (en) * | 2011-12-19 | 2017-04-11 | Emmaus Medical, Inc. | Methods and compositions for the treatment of diverticulosis |
AU2013204801B2 (en) | 2012-05-23 | 2014-11-06 | Omniblend Innovation Pty Ltd | Composition and method for management of diabetes or pre-diabetes |
DE102012222641A1 (de) | 2012-12-10 | 2014-06-12 | BSH Bosch und Siemens Hausgeräte GmbH | Kältegerät mit Schwenkladenvorrichtung |
US20150024070A1 (en) | 2013-07-18 | 2015-01-22 | Plato Chun-Chih Lee | Ingestible canker sore treatment |
WO2017050629A1 (en) * | 2015-09-21 | 2017-03-30 | Dsm Ip Assets B.V. | Yeast cell wall derived flavour |
TWI777673B (zh) * | 2021-07-16 | 2022-09-11 | 陳昭誠 | 由β-1-4-葡聚醣形成之纖維於製備用於治療或預防胃食道逆流之組成物之用途 |
WO2023002252A1 (en) | 2021-07-21 | 2023-01-26 | Bioatlantis Limited | Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS505568A (ja) * | 1973-05-16 | 1975-01-21 | ||
JPH04505997A (ja) * | 1988-10-28 | 1992-10-22 | アルフア・ベータ・テクノロジー | グルカンの食物添加物 |
JP2001514523A (ja) * | 1997-03-13 | 2001-09-11 | アボット・ラボラトリーズ | 加水分解タンパク質および繊維ブレンドを含む栄養組成物 |
JP2002510317A (ja) * | 1997-07-02 | 2002-04-02 | アボット・ラボラトリーズ | 味のよい基本医用組成物 |
JP2002512011A (ja) * | 1998-04-17 | 2002-04-23 | オールテック インコーポレイテッド | 飼料の脱マイコトキシン用組成物 |
JP2002241784A (ja) * | 2001-02-15 | 2002-08-28 | Asahi Denka Kogyo Kk | βグルカン含有油脂組成物 |
JP2004051582A (ja) * | 2002-07-23 | 2004-02-19 | Ajinomoto General Foods Inc | マンノオリゴ糖を含有する免疫賦活組成物 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1526553A (en) * | 1975-02-06 | 1978-09-27 | Du Pont Canada | Extraction of oil from oats |
US4752618A (en) * | 1984-07-12 | 1988-06-21 | New England Deaconess Hospital | Method of minimizing efects of infection through diet |
US4729896A (en) * | 1986-06-23 | 1988-03-08 | Pacific Kenyon Corp. | Buffered animal feed supplement block |
US4950656A (en) * | 1987-02-17 | 1990-08-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
GB8710041D0 (en) * | 1987-04-28 | 1987-06-03 | Cadbury Schweppes Plc | Viscosity reducing agent |
US5312636A (en) * | 1987-08-12 | 1994-05-17 | Valtion Teknillinen Tutkimuskeskus | Process for fractioning crop into industrial raw material |
US4847095A (en) * | 1987-09-11 | 1989-07-11 | Wendland's Farm Products, Inc. | Method for free choice horse feeding |
EP0371601B1 (en) * | 1988-10-29 | 1995-02-15 | Cadbury Schweppes Plc | Surfactant |
US6020324A (en) * | 1989-10-20 | 2000-02-01 | The Collaborative Group, Ltd. | Glucan dietary additives |
US5320846A (en) * | 1991-04-17 | 1994-06-14 | New England Deaconess Hospital Corp. | Method and composition for testing patients with metabolic depleting diseases |
US5589186A (en) * | 1993-01-29 | 1996-12-31 | Takeda Chemical Industries, Ltd. | Feed composition for ruminant animals and method of feeding ruminant animals with the same |
DE69418378T2 (de) * | 1993-02-09 | 1999-12-16 | Quaker Oats Co | Verfahren zur Herstellung einer transparenten, stabilen wässrigen Lösung von Haferproteinen, mit niedrigem Fettgehalt, und Produkt daraus |
ES2123644T3 (es) * | 1993-04-07 | 1999-01-16 | Lovesgrove Res Ltd | Alimento para animales. |
US5505968A (en) * | 1993-07-02 | 1996-04-09 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture | Antemortem nutrient supplement for livestock |
DK0743851T3 (da) * | 1994-02-04 | 2001-09-03 | Lipocore Holding Ab | Lipofile bærepræparater |
GB9418420D0 (en) * | 1994-09-13 | 1994-11-02 | Mckeown Neil A | Composition for the treatment of an energy imbalance in ruminents |
EP0711503A3 (en) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
DE69606638T2 (de) * | 1995-06-01 | 2000-07-20 | Unilever Nv | Fettenthaltende nahrungsmittelprodukte |
SE504664C2 (sv) * | 1995-09-22 | 1997-03-24 | Scotia Lipidteknik Ab | Sätt att framställa fraktionerad olja, oljan, dess användning samt emulsionskomposition innehållande oljan |
US6200624B1 (en) * | 1996-01-26 | 2001-03-13 | Abbott Laboratories | Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids |
JPH09262061A (ja) * | 1996-03-28 | 1997-10-07 | Tanabe Seiyaku Co Ltd | ストレス緩和用飼料 |
CA2208827C (en) * | 1996-07-09 | 2006-01-03 | Ben A. Steensma | Animal feed |
CA2284290A1 (en) * | 1997-03-20 | 1998-09-24 | Samuel Russell Vester | Nutritional supplement for cardiovascular health |
SE9702630D0 (sv) * | 1997-07-07 | 1997-07-07 | Scotia Lipidteknik Ab | Satiety product |
US6423363B1 (en) * | 1997-08-22 | 2002-07-23 | Lipton, Division Of Conopco, Inc. | Aqueous dispersion |
SE511025C2 (sv) * | 1997-10-03 | 1999-07-26 | Probi Ab | Foderprodukt för häst omfattande Lactobacillus plantarum JI:1 samt Lactobacillus plantarum JI:1 och användning därav |
US5972985A (en) * | 1997-11-03 | 1999-10-26 | Cytos Pharmaceuticals, Llc | Histidine containing nutriceutical compositions |
US6060519A (en) * | 1998-08-07 | 2000-05-09 | The United States Of America As Represented By The Secretary Of Agriculture | Soluble hydrocolloid food additives and method of making |
US20020054917A1 (en) * | 1998-08-14 | 2002-05-09 | Gohlke Marcus B. | Compositions comprising beta glucan and lactoferrin, and methods for their use |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
SE9804192D0 (sv) * | 1998-12-03 | 1998-12-03 | Scotia Lipidteknik Ab | New formulation |
WO2000065928A1 (en) * | 1999-05-03 | 2000-11-09 | Alltech, Incorporated | Novel compositions and methods for reduction of effects of endophyte-infected forages |
US6117458A (en) * | 1999-06-01 | 2000-09-12 | Morgan; Norma B. | Swine feed composition |
US6410067B1 (en) * | 2000-01-27 | 2002-06-25 | Morton Jay Kanter | Equine neutraceuticals |
US6451370B1 (en) * | 2000-05-25 | 2002-09-17 | Tom Anderson | Complete animal feed with potato component |
US20020044988A1 (en) * | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
WO2002067966A1 (en) * | 2001-02-22 | 2002-09-06 | Purdue Research Foundation | Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer |
JP4618952B2 (ja) * | 2001-09-10 | 2011-01-26 | 日本ケンタッキー・フライド・チキン株式会社 | 揚げ物の製造方法 |
US6835558B2 (en) * | 2002-02-04 | 2004-12-28 | General Mills, Inc. | Beta-glucan compositions and process therefore |
US7824706B2 (en) * | 2003-05-09 | 2010-11-02 | Freedom Health, Llc | Dietary supplement and method for the treatment of digestive tract ulcers in equines |
US7988989B2 (en) * | 2003-05-09 | 2011-08-02 | Freedom Health, Llc | Nutritional product for enhancing growth and/or strengthening the immune system of equine foals |
FI20031004A0 (fi) | 2003-07-03 | 2003-07-03 | Raisio Benecol Oy | Uusi syötävä koostumus |
JP3729188B2 (ja) * | 2003-07-07 | 2005-12-21 | ヱスビー食品株式会社 | 粉末状食品およびその製造法 |
-
2004
- 2004-09-22 US US10/947,598 patent/US20050058671A1/en not_active Abandoned
- 2004-11-03 JP JP2007503889A patent/JP2007529220A/ja active Pending
- 2004-11-03 AU AU2004317895A patent/AU2004317895B2/en active Active
- 2004-11-03 WO PCT/US2004/036720 patent/WO2005094234A2/en active Application Filing
- 2004-11-03 KR KR1020067021436A patent/KR20070006843A/ko not_active Application Discontinuation
- 2004-11-03 MX MXPA06010503A patent/MXPA06010503A/es not_active Application Discontinuation
- 2004-11-03 CA CA2559755A patent/CA2559755C/en active Active
- 2004-11-03 BR BRPI0418681-8A patent/BRPI0418681A/pt not_active Application Discontinuation
- 2004-11-03 EP EP04800719A patent/EP1729809A4/en not_active Ceased
- 2004-11-07 JO JO2004157A patent/JO2792B1/en active
- 2004-11-10 AR ARP040104150A patent/AR047308A1/es not_active Application Discontinuation
- 2004-11-10 TW TW093134298A patent/TWI367728B/zh active
-
2013
- 2013-05-08 JP JP2013098495A patent/JP2013146281A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS505568A (ja) * | 1973-05-16 | 1975-01-21 | ||
JPH04505997A (ja) * | 1988-10-28 | 1992-10-22 | アルフア・ベータ・テクノロジー | グルカンの食物添加物 |
JP2001514523A (ja) * | 1997-03-13 | 2001-09-11 | アボット・ラボラトリーズ | 加水分解タンパク質および繊維ブレンドを含む栄養組成物 |
JP2002510317A (ja) * | 1997-07-02 | 2002-04-02 | アボット・ラボラトリーズ | 味のよい基本医用組成物 |
JP2002512011A (ja) * | 1998-04-17 | 2002-04-23 | オールテック インコーポレイテッド | 飼料の脱マイコトキシン用組成物 |
JP2002241784A (ja) * | 2001-02-15 | 2002-08-28 | Asahi Denka Kogyo Kk | βグルカン含有油脂組成物 |
JP2004051582A (ja) * | 2002-07-23 | 2004-02-19 | Ajinomoto General Foods Inc | マンノオリゴ糖を含有する免疫賦活組成物 |
Non-Patent Citations (1)
Title |
---|
JPN6009036928, Food Biotechnology, vol.15, p.1−12 (2001) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012503615A (ja) * | 2008-09-26 | 2012-02-09 | バイオイベリカ ソシエダッド アノニマ | ヌクレオ塩基(nucleobase)と、真菌類、酵母、または細菌から得られる多糖と、を含む免疫刺激剤組成物 |
JP2013095702A (ja) * | 2011-11-01 | 2013-05-20 | Daiso Co Ltd | β−1,3−グルカンを含む過敏性腸症候群の下痢抑制剤、腹痛改善剤、及び大腸における痛覚過敏改善剤 |
JP2017522308A (ja) * | 2014-07-21 | 2017-08-10 | ネステク ソシエテ アノニム | 安全な嚥下を促進する嚥下障害者用栄養製品 |
JP7431842B2 (ja) | 2018-10-15 | 2024-02-15 | フリーダム ヘルス,エルエルシー | 消化器系及び免疫系の障害を治療する為のヒト用栄養補助食品 |
Also Published As
Publication number | Publication date |
---|---|
AR047308A1 (es) | 2006-01-18 |
MXPA06010503A (es) | 2006-12-19 |
TW200531640A (en) | 2005-10-01 |
AU2004317895B2 (en) | 2010-09-16 |
JO2792B1 (en) | 2014-03-15 |
AU2004317895A1 (en) | 2005-10-13 |
CA2559755A1 (en) | 2005-10-13 |
EP1729809A2 (en) | 2006-12-13 |
US20050058671A1 (en) | 2005-03-17 |
WO2005094234A2 (en) | 2005-10-13 |
BRPI0418681A (pt) | 2007-06-12 |
TWI367728B (en) | 2012-07-11 |
EP1729809A4 (en) | 2008-02-13 |
KR20070006843A (ko) | 2007-01-11 |
WO2005094234A3 (en) | 2006-09-28 |
CA2559755C (en) | 2012-08-07 |
JP2013146281A (ja) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013146281A (ja) | 栄養補助食品 | |
JP2010162040A (ja) | 栄養補助食品及び消化器系関連障害の治療方法 | |
ES2272715T5 (es) | Un sistema de fibras de viscosidad inducida controlada por ácido y utilización de este sistema. | |
RU2395218C2 (ru) | Композиция пищевых волокон для профилактики или лечения заболеваний пищеварительной системы и композиция пищевых волокон, эффективная при лечении холеры | |
WO2013032744A2 (en) | Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum | |
KR20040105737A (ko) | 우유 미네랄과 카세인 분절을 사용하는 체중 상태 치료용조성물 및 방법 | |
CN105029447A (zh) | 一种含有活性益生菌的海洋鱼低聚肽粉 | |
CA2316671A1 (en) | Nutritional products and method for treating and preventing cancer and other degenerative diseases | |
WO2008140064A1 (ja) | 生活習慣病の予防および改善のための栄養組成物 | |
JPH10306028A (ja) | 脂質消化吸収阻害整腸剤 | |
Krueger et al. | Nutritional supplements and alternative medicine | |
ES2899639T3 (es) | Betaína para la prevención de la obesidad | |
EP3866615B1 (en) | Dietary supplement for treating dysbiosis | |
US20050003027A1 (en) | Chemical composition and method to bind fat, enhance metabolization, and aid digestion | |
WO2000054792A1 (fr) | Medicaments, aliments, boissons et aliments pour animaux contenant un composant de cacao | |
JPS60112720A (ja) | 肝臓疾患治療効果を有する薬剤 | |
RU2295873C1 (ru) | Способ похудения | |
Murray | Arthritis: Your Natural Guide to Healing With Diet, Vitamins, Minerals, Herbs, Exercise, and Other Natural Methods | |
RU2407404C2 (ru) | Способ похудения | |
Dharmarajan | Psyllium versus guar gum: facts and comparisons | |
RU2431471C1 (ru) | Биологически активная композиция для контроля и управления аппетитом и регулирования веса | |
Borwell et al. | Dietary considerations following stoma surgery | |
JPS5913733A (ja) | 循環器系疫病治療効果を有する飲食品 | |
Lam | The Latest on Body Cleansing and Detoxification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071022 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091019 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091117 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100304 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100317 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100329 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100416 |